首页> 美国卫生研究院文献>Diabetology Metabolic Syndrome >Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week multicenter parallel-group randomized controlled trial

【2h】

Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week multicenter parallel-group randomized controlled trial

机译：在日本2型糖尿病患者中西他列汀单药治疗比格列美脲单药治疗对胰岛素生成指数的效果更好：一项为期52周多中心平行组的随机对照试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThe 52-week monotherapy with the dipeptidyl peptidase-4 inhibitor sitagliptin and the sulphonylurea glimepiride on early-phase insulin secretion in Japanese patients with type 2 diabetes mellitus (T2DM) is not known.

机译：背景在日本2型糖尿病（T2DM）患者中，使用二肽基肽酶4抑制剂西他列汀和磺酰脲类格列美脲进行52周的单药治疗对早期胰岛素分泌的作用尚不清楚。

著录项

期刊名称 Diabetology Metabolic Syndrome
作者
Yaeko Kondo; Norio Harada; Akihiro Hamasaki; Shizuka Kaneko; Koichiro Yasuda; Eiichi Ogawa; Shin-ichi Harashima; Hiroko Yoneda; Yoshihito Fujita; Norikazu Kitano; Yoshio Nakamura; Fujio Matsuo; Megumi Shinji; Shiro Hinotsu; Takeo Nakayama; Nobuya Inagaki;
展开▼
作者单位

展开▼
年(卷),期 2016(8),-1
年度 2016
页码 15
总页数 9
原文格式 PDF
正文语种
中图分类基础医学;
关键词
Clinical trial Type 2 diabetes Insulin secretion DPP-4 inhibitor Sulphonylurea;

机译：临床试验;2型糖尿病;胰岛素分泌;DPP-4抑制剂;磺酰脲;

相似文献

外文文献
中文文献
专利

1. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. [J] . Yukio Tanizawa, Kohei Kaku, Eiichi Araki, Expert opinion on pharmacotherapy . 2014,第6期

机译：Tofogliflozin（一种钠-葡萄糖共转运蛋白2的选择性抑制剂）在日本2型糖尿病患者中的单药治疗或与其他口服抗糖尿病药的长期安全性和有效性：多中心，开放标签，随机对照试验。
2. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. [J] . Arechavaleta R, Seck T, Chen Y, Diabetes, obesity & metabolism . 2011,第2期

机译：西他列汀或格列美脲治疗二甲双胍单药治疗不能充分控制的2型糖尿病的疗效和安全性：一项随机，双盲，非劣效性试验。
3. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study [J] . Kohei Kaku, Hirotaka Watada, Yasuhiko Iwamoto, Cardiovascular Diabetology . 2014,第1期

机译：新型钠/葡萄糖共转运蛋白2抑制剂tofogliflozin在日本2型糖尿病患者中单药治疗的有效性和安全性：一项2期和3期随机，安慰剂对照，双盲，平行组比较研究
4. ACE inhibition in asymptomatic MR dogs: results from a 4 year prospective, double blind, placebo controlled, monotherapy trial (SVEP = scandinavian veterinary enalapril prevention trial) [C] . Clarence Kvart, Jens Haggstrom, Henrik Duelund Pedersen Annual Veterinary Medical Forum . 2000

机译：ACE抑制无症状的狗：4年前瞻性，双盲，安慰剂控制，单药治疗试验的结果（SVEP =斯堪的纳维亚兽医enalapril预防审判）
5. A 4-month randomized controlled clinical trial of adjuvant Exenatide or Pramlintide versus insulin alone in pediatric type 1 diabetes mellitus: Effect on glycemic control. [D] . Withycombe, Sarah Elizabeth. 2010

机译：儿科1型糖尿病患者中艾塞那肽或普兰林肽与单独使用胰岛素的4个月随机对照临床试验：对血糖控制的影响。
6. Efficacy and Safety of Lobeglitazone Monotherapy in Patients with Type 2 Diabetes Mellitus over 24-Weeks: A Multicenter Randomized Double-Blind Parallel-Group Placebo Controlled Trial [O] . Sin Gon Kim, Doo Man Kim, Jeong-Taek Woo, -1

机译：雷贝格列酮单药治疗24周内2型糖尿病患者的疗效和安全性：多中心随机双盲平行组安慰剂对照试验
7. Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial [O] . 2016

机译：在日本2型糖尿病患者中，西格列汀单药治疗比格列美脲单药治疗对胰岛素生成指数的效果更好：一项为期52周，多中心，平行组的随机对照试验

Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week multicenter parallel-group randomized controlled trial

摘要

著录项

相似文献

相关主题

期刊订阅